This policy does not certify benefits or authorization of benefits, which is designated by each individual policyholder contract. Paramount applies coding edits to all medical claims through coding logic software to evaluate the accuracy and adherence to accepted national standards. This guideline is solely for explaining correct procedure reporting and does not imply coverage and reimbursement.
Advantage and Elite
Viscosupplementation using Synvisc or Synvisc-One (J7325) for osteoarthritis of the knee does not require prior authorization.
Viscosupplementation using other brands (C9465, J7320-J7324, J7326-J7328) is non-covered.
HMO, PPO, Individual Marketplace
The use of viscosupplementation (C9465, J7320-J7328) is not covered for osteoarthritis of the knee or for any other indications. There is no clinical significant evidence supporting intraarticular hyaluronic acid injection(s) decrease knee arthroplasty.
Advantage, Elite
An initial course of viscosupplementation (J7325) is considered medically necessary for the treatment of pain due to osteoarthritis of the knee when ALL of the following criteria are met:
1. There is documentation of a diagnosis of osteoarthritis and there is no evidence of inflammatory arthritis (for example, rheumatoid arthritis). 2. There is documentation that the pain interferes with functional activities (for example, ambulation, prolonged standing). 3. There is documentation of failure to respond adequately to at least 3 months of conservative therapy which includes activity modification, home exercise, protective weight bearing, and analgesics (for example, acetaminophen or non-steroidal anti-inflammatory drugs [NSAIDs] ) or the individual is unable to tolerate conservative therapy because of adverse side effects. 4. There are no contraindications to the injections (for example, active joint infection, bleeding disorder).
A repeat course of viscosupplementation (J7325) is considered medically necessary for the treatment of pain due to osteoarthritis of the knee for individuals who meet ALL of the following criteria:
1. The individual met all of the criteria for an initial course of treatment.
2. Six (6) months, or more, have elapsed since the conclusion of the prior treatment cycle.
3. There is documentation that the prior course of treatment resulted in pain relief and improvement in functional status.
Paramount does not cover viscosupplementation for the treatment of osteoarthritis in locations other than the knee because it is considered experimental, investigational or unproven.
Viscosupplementation (J7325) for osteoarthritis of the knee should be reported with injection procedure code 20610. Procedures J7325 will be denied when reported with procedures 20600, 20604, 20605, 20606, for locations other than the knee (e.g. temporomandibular, acromioclavicular, wrist, elbow, or ankle, olecranon bursa).
Note: Ultrasound guidance, fluoroscopic guidance and knee arthrography for viscosupplement injections is considered experimental and investigational because it has not been established that this approach will improve health outcomes.
Preferred and Medically Necessary Brand of Viscosupplement:
There are several brands of viscosupplement on the market. There is a lack of reliable evidence that any one brand of viscosupplement is superior to other brands for medically necessary indications.
Consequently, because other brands of viscosupplement are at least as likely to produce equivalent therapeutic results, no other brands of viscosupplement (C9465, J7320-J7324, J7326-J7328) will be considered medically necessary unless the member has a documented contraindication or intolerance to Paramount's preferred brand of viscosupplement: Synvisc or Synvisc-One (J7325).
Documentation Requirements:  All documentation must be maintained in the patient's medical record and made available upon request.  Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service(s)). The documentation must include the legible signature of the physician or non-physician practitioner responsible for and providing the care to the patient.  The submitted medical record must support the use of the selected ICD-10-CM code(s). The submitted CPT/HCPCS code must describe the service performed.  The medical record documentation must support the medical necessity of the services as directed in this policy.  An appropriate diagnosis code must be submitted on the claim. The patient's medical record should indicate the signs/symptoms supporting the diagnosis and functional impairment. The appropriate records documenting the improvement must be maintained in the medical record and made available to Medicare upon request.  An X-ray report of the knees must be available in the event of a review.  Medical records should reflect failure of conservative treatment defined as physical therapy and use of simple non-narcotic analgesics including acetaminophen.  When billing for a drug/biological, any amount of medication wasted must be clearly documented in the medical record. The documentation must include the date, time, amount of medication wasted, and the reason for the wastage. 
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